SI-BONE, Inc.
SI-BONE, Inc. (SIBN) Financial Performance & Income Statement Overview
Analyze SI-BONE, Inc. (SIBN) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
SI-BONE, Inc. (SIBN) Income Statement & Financial Overview
Analyze SI-BONE, Inc.’s SIBN earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $47.29M | $49.002M | $40.34M | $39.97M |
| Cost of Revenue | $9.60M | $10.22M | $8.44M | $8.39M |
| Gross Profit | $37.70M | $38.78M | $31.90M | $31.58M |
| Gross Profit Ratio | $0.80 | $0.79 | $0.79 | $0.79 |
| R&D Expenses | $4.53M | $3.87M | $3.99M | $4.35M |
| SG&A Expenses | $40.64M | $40.40M | $35.54M | $37.30M |
| Operating Expenses | $45.17M | $44.27M | $39.54M | $41.65M |
| Total Costs & Expenses | $54.77M | $54.50M | $47.97M | $50.05M |
| Interest Income | $1.59M | $1.78M | $1.94M | $2.02M |
| Interest Expense | $662000.00 | $793000.00 | $884000.00 | $880000.00 |
| Depreciation & Amortization | $1.28M | $1.21M | $1.08M | $992000.00 |
| EBITDA | -$4.60M | -$2.49M | -$4.61M | -$7.07M |
| EBITDA Ratio | -$0.10 | -$0.05 | -$0.11 | -$0.18 |
| Operating Income | -$7.48M | -$5.49M | -$7.63M | -$10.08M |
| Operating Income Ratio | -$0.16 | -$0.11 | -$0.19 | -$0.25 |
| Other Income/Expenses (Net) | $938000.00 | $999000.00 | $1.06M | $1.14M |
| Income Before Tax | -$6.54M | -$4.50M | -$6.58M | -$8.94M |
| Income Before Tax Ratio | -$0.14 | -$0.09 | -$0.16 | -$0.22 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$6.54M | -$4.50M | -$6.58M | -$8.94M |
| Net Income Ratio | -$0.14 | -$0.09 | -$0.16 | -$0.22 |
| EPS | -$0.15 | -$0.11 | -$0.16 | -$0.22 |
| Diluted EPS | -$0.15 | -$0.11 | -$0.16 | -$0.22 |
| Weighted Avg Shares Outstanding | $42.34M | $41.99M | $41.72M | $41.32M |
| Weighted Avg Shares Outstanding (Diluted) | $42.34M | $41.99M | $41.72M | $41.32M |
The company's financials show resilient growth, with revenue advancing from $39.97M in Q2 2024 to $47.29M in Q1 2025. Gross profit remained healthy with margins at 80% in Q1 2025 compared to 79% in Q2 2024. Operating income hit -$7.48M last quarter, sustaining a consistent -16% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$4.60M. Net income dropped to -$6.54M, while earnings per share reached -$0.15. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan